Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers (NCT05940272)
Evaluation of a Communication Intervention (Hematolo-GIST) for Large B-Cell Lymphoma Providers
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to develop and test a new communication training intervention called Hematolo-GIST to help oncologists communicate with patients about their lymphoma diagnosis and advance care planning.
Who can join: Review the eligibility criteria below.
Location: Memorial Sloan Kettering Cancer Center (All protocol activities) — New York, New York
Age range: 18 Years
🧪 Interventions in This Study
- Hematolo-GIST Training (BEHAVIORAL)
- Participants Appointment (BEHAVIORAL)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (2 Sites)
- Memorial Sloan Kettering Cancer Center (All protocol activities) — New York, New York
- NEW YORK PRESBYTERIAN HOSPITAL (Data Collection Only) — New York, New York
📞 Contact the Study Coordinator
Phone: (646) 888-0026
Email: McConneK@mskcc.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Lymphoma, B-Cell
- A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) — Scottsdale, Arizona
- FT819 in Subjects With B-cell Malignancies — Birmingham, Alabama
- Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma — Vancouver, British Columbia
- Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. — Burbank, California
- Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma — Birmingham, Alabama
Explore by condition: All Lymphoma, B-Cell clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.